As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

AstraZeneca Plc and Daiichi's breast cancer drug Enhertu is based off of Daiichi's antibody-drug conjugate platform DXd, and ...

Enhertu is already approved for patients with ... could give it an edge over class rival Verzenio from Eli Lilly. The success of clinical trials hinges on a complex array of factors, many of ...

Adleb is a Waikato-bred rapper, producer, and lyricist, igniting stages with his raw energy and unparalleled flow. Blending ...

Appleby House are excited to announce Appleby Vibes – Tasman’s newest music event, is launching with a bang and bringing Drax ...

It remains to be seen though if Tukysa could also be combined with Enhertu to good effect ... according to a new study. The success of clinical trials hinges on a complex array of factors ...

At the European Society of Medical Oncology (ESMO) Congress 2024, recent results from the single-arm open-label DESTINYBreast-012 trial evaluating Daiichi Sankyo’s Enhertu (trastuzumab ...

The Japanese cancer drug powerhouse Daiichi Sankyo has its sights on the next generation of targeted oncology drugs, and this ...

J.P. Morgan analyst James Gordon reiterated a Buy rating on AstraZeneca (AZN – Research Report) today. The company’s shares closed ...